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Abstract 
Background. Severe mental illness (SMI) is thought to be associated with lower diet quality 
and adverse eating behaviours contributing towards the physical health disparities. A 
rigorous review of the studies looking at dietary intake in psychotic disorders and bipolar 
disorder is lacking.  
Aim. To conduct a systematic, comprehensive evaluation of the published research on 
dietary intake in psychotic disorders and bipolar disorder.  
Methods. Six electronic databases were searched for studies reporting on dietary intakes in 
psychotic disorders and bipolar disorder. Dietary assessment methods, and dietary intakes, 
were systematically reviewed. Where possible, data was pooled for meta-analysis and 
compared to healthy controls.  
Results. Fifty-eight eligible studies were identified. People with SMI were found to have 
significantly higher dietary energy (MD = 1,332kJ, 95% C.I. +487 to +2,178kJ/day, p = 0.002, 
g = 0.463) and sodium (MD = 322mg, 95% C.I. 174 to 490mg, p<0.001, g=0.414) intake 
compared to controls. Qualitative synthesis suggested that higher energy and sodium 
intakes were associated with poorer diet quality and eating patterns.  
Conclusion. These dietary components should be key targets for preventative intervention 
to improve weight and other physical health outcomes in people with SMI.  
 
Declaration of Interest. SBT and ET have clinical dietitian appointments within the South 
Eastern Sydney Local Health District and do not receive any further funding. JF is supported 
by a Blackmores Institute Fellowship and an MRC Doctoral Training Grant (P117413F07). 
BS is part funded by the National Institute for Health Research (NIHR) Biomedical Research 
Centre at South London and Maudsley NHS Foundation Trust and King’s College London. 
The views expressed are those of the author(s) and not necessarily those of the NHS, the 
NIHR or the Department of Health. TB is supported by a Brawn research fellowship, 
University of Newcastle. 
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Introduction 
People with severe mental illness (SMI) die approximately 15 years earlier than individuals in 
the general population [1], identified as a significant human rights issue and major source of 
inequity [2].  The vast majority of these earlier deaths are attributable to physical health 
conditions, primarily cardiovascular disease [3].  Understanding modifiable factors that may 
diminish or prevent the “scandal of premature mortality” is essential [2].  In the general 
population, there is robust evidence that excessive energy intake and poor diet quality is 
associated with adverse physical health including cardiovascular disease and premature 
mortality [4]. This evidence supports population-level state-sanctioned strategies that focus 
on nutrition as a cornerstone of health outcome determination.  
 
For many people experiencing SMI, antipsychotic, anti-depressant and mood-stabilising 
medications may be essential components of treatment [5, 6]. Many of these medications 
are associated with substantial weight gain, obesity and associated cardiometabolic 
abnormalities [7-9]. It has been suggested that one of the key factors underlying these 
abnormalities are the effects of antipsychotic medication (APM) on dietary intake and eating 
behaviours [10]. People receiving APM report increased appetite, decreased satiety and 
increased cravings for sweet foods and beverages [11]. A range of lifestyle interventions 
have attempted to mitigate the obesogenic effects of these medications, however a clear 
understanding of the dietary intake in people experiencing psychotic illness is lacking.  A key 
limitation in a previous systematic review of dietary patterns in schizophrenia [12], was lack 
of evaluation and critique of the quality of dietary intake assessment methods. Given the 
vast majority of dietary assessment methods are subjective, the strength of methodology in 
collecting, interpreting and analyzing dietary intakes is a crucial determinant for obtaining 
meaningful conclusions. Thus, a comprehensive systematic review and meta-analysis of the 
dietary intake of people with SMI, taking into account dietary assessment methodology, is 
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warranted to identify possible dietary treatment targets for interventions to improve the 
physical health of this vulnerable population.  
 
Methods 
Design 
This study was pre-registered on the PROSPERO database (CRD42016048833) and 
conducted in accordance with the PRISMA [13] and MOOSE statements [14] (see 
Supplementary Files 1 and 2 for PRISMA and MOOSE checklists). 
 
Search Strategy 
An online search strategy was undertaken to identify studies published in the English 
language from 1975 to August 2017 through librarians within the University of Newcastle, 
Callaghan Campus. Cumulative Index to Nursing and Allied Health Literature (CINAHL), 
Cochrane, Embase, Medline, PsychINFO and Scopus databases were searched using 
common psychiatric and nutritional MeSH terms (feeding behavior OR eating OR food intake 
OR diet* OR nutrition* OR coffee OR caffeine OR beverages AND schizophrenia OR 
psychotic disorders OR bipolar disorder OR bipolar*; see Supplementary File 3 for 
comprehensive search list). Electronic searches were supplemented with manual 
crosschecking of the reference lists of relevant publications [12]. Cross-sectional and cohort 
studies in adults were included.  
 
After the removal of duplicates, stage 2 involved the assessment of titles and abstracts of 
identified studies by two independent reviewers (ST and TB), with disagreements resolved 
by further discussion. A priori inclusion/exclusion criteria were applied to determine the 
eligibility of each publication for inclusion in the review, as per the following inclusion criteria; 
 
Population: Adult populations (age ≥ 18 years or “adults” depending on the database 
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searched), Diagnostic and Statistical Manual of Mental Disorders (DSM) or International 
Statistical Classification of Disease and Related Health Problems (ICD) diagnosis of a 
severe mental illness (schizophrenia spectrum disorders, bipolar affective disorder, 
depression with psychosis, or other psychotic illness) or clinician diagnosed first-episode of 
psychosis. There were no limitations employed for rates of psychotropic medication 
prescription, as reporting of this was infrequently included. 
Intervention: Types of studies included cross-sectional, cohort and longitudinal designs.  
Control: There were no limits on comparison groups, although only studies with matched 
controls were eligible for meta-analysis.  
Outcome: One or more nutritional outcomes, including energy, macronutrients, 
micronutrients, fat subgroups, fibre, diet quality, food groups and caffeine.  
 
We excluded animal studies, studies of people with high-prevalence mental illness 
(depression and anxiety), or those with eating disorders (anorexia and bulimia nervosa), 
case studies, letters to the editor, intervention studies, and studies with eating behaviour 
outcomes that lacked specific dietary intake outcomes. Alcohol was excluded as an outcome 
as we did not include substance use in our search terms. Excluded articles are summarized 
in Figure 1.  
 
Data extraction. Where necessary, corresponding authors of included studies were 
contacted for additional data for inclusion in meta-analysis. A follow-up email was sent three 
weeks later if corresponding authors did not reply to the initial request.  
 
Data were extracted using standardised tables developed for this review and included study 
design, population demographics, and dietary intake assessment methods. In cases of 
uncertainty regarding quality assessment, or data extraction, a third independent reviewer 
was consulted, until consensus was reached.  
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Study quality. Study quality was assessed twice for each individual study using a 
standardised tool from the American Academy of Nutrition and Dietetics [15]. Two reviewers 
scored each study independently. The lead author resolved discrepancies between the 
different scorers. Scoring included ten quality criteria that were rated as being absent, 
present or unclear in each study. This included the assessment of population bias, study 
blinding, a description of the assessment tool, statistical methods and study funding. An 
overall quality rating was assigned, with each study being rated as: (i) negative (-) if 6 or 
more answers to the validity questions are ‘No’, (ii) Neutral (∅) if answers to validity criteria 
2, 3, 6 and 7 do not indicate the study was strong, or (iii) positive (+) if most of the answers 
to validity criteria were ‘Yes’ (including criteria 2, 3, 6 and 7 plus one extra criteria). No 
studies were excluded based on quality ratings. 
 
Data-analysis  
Studies were eligible for meta-analysis if they; (i) utilised a recognised dietary assessment 
method (i.e. 24-hour recall) or cited a validation study for the tool utilised, (ii) had a matched 
control group who were assessed at the same time as the target group, and (iii) reported 
outcomes in a compatible metric/measure. Comparisons against national health surveys and 
other population data sources were not eligible for meta-analysis. 
 
All meta-analyses were performed using Comprehensive Meta-Analysis 2.0 [16]. To account 
for expected heterogeneity between studies, a random-effects model was used throughout 
[17]. First, for studies that utilised validated, or recognised and acceptable, dietary 
assessment tools, comparative meta-analyses were performed to calculate a pooled mean 
difference (and 95% confidence intervals) between SMI and healthy control samples in daily 
total energy intake, the primary outcome of interest, measured in kilojoules per day (kJ).  
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As secondary outcomes, we also compared SMI and control groups on daily mean intake of 
each macronutrient and micronutrient, examined in a sufficient number of studies to justify 
meta-analysis (>2), using the standard units of measurements for these nutrients. If 
nonstandard means were used, we calculated means and standard deviations (SD) from the 
data of the studies where possible. Along with examining differences using standard nutrient 
measurement values, the overall difference between SMI and control groups for daily intake 
of each macro/micronutrient was computed as Hedge’s G, with resultant effect sizes 
classified as small (<0.2), moderate (>0.2, <0.8) or large (>0.8). Statistical significance was 
set at p<0.05. For all analyses, the variance between studies was assessed using Cochran’s 
Q and reported as I2, which quantifies the degree of variance resulting from between-study 
heterogeneity, rather than by chance. 
 
For the primary outcome, we also applied several tests to measure and adjust for publication 
bias: (i) Egger’s regression test was used to quantify the risk of publication bias influencing 
findings, (ii) the ‘Fail-Safe N’ [18] was calculated to determine the number of unpublished 
null studies which would invalidate the findings, and (iii) Duval and Tweedie’s trim-and-fill 
analysis was used to re-calculate the pooled difference after adjusting for any studies 
potentially reflecting publication bias.
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Results 
Identification and Selection of Studies.  
Electronic database searches identified 5,538 unique titles after accounting for 
duplicates, as summarised in Figure 1. Five additional titles were sourced by screening 
a relevant references [12]. A review of titles and abstracts led to the exclusion of 5,394 
titles. Full-texts were assessed for the remaining 149 titles, of which 91 were excluded 
for reasons detailed in figure 1. Fifty-eight studies were identified for critical appraisal 
and included in this review [19-76].  
 
Insert figure 1 about here 
 
The studies were conducted in 17 countries, with the majority conducted in the USA 
(N=14 studies, n=4,885 participants), UK (N=10, n=575), Spain (N=6, n=2,637) and 
Australia (N=6, n=1,899). The majority of studies were cross-sectional in design (N=48, 
n=33,915), whilst smaller numbers of cohort (N=6, n=924), and case control (N=2, 
n=275) studies were included, and one study each for longitudinal (n=352) and cross-
cue reactivity (n=15). 
 
Characteristics of Included Studies.  
Participants. The 58 studies included a total of 35,481 people with SMI and 
5,465 non-psychiatric controls. Diagnoses within the studies were: (i) limited to 
schizophrenia spectrum disorders (N= 27, 47%, n=26,230), (ii) mixed SMI diagnoses 
(N=20, 34%, n=8,301), (iii) limited to bipolar affective disorder (N=7, 12%, n=673), and 
(iv) limited to first-episode psychosis (N=4, 7%, n=277). The majority of studies 
described participants as outpatients or community-dwelling (N=40, n=6,944), followed 
by inpatients (N=8, n=886) and mixed settings (N=2, n=22,072). Eight studies did not 
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report participant setting. Nineteen studies (33%) used controls (n=5,465) and 20 
studies (34%) used population data as a comparator group. Participants were receiving 
a range of psychotropic medications including antipsychotics, mood stabilisers, 
antidepressants and benzodiazepine medications. Medications were reported in a 
range of formats including (i) chlorpromazine equivalents, (ii) percent on psychotropic 
medications as a whole, (iii) percent prescribed APM or generation of APM and APM 
polypharmacy, (iv) percent prescribed mood stabiliser medication, and (iv) percent of 
prescription of individual medications. Seventeen studies (29%) did not describe 
medication prescription. See Supplementary File 4 for complete details.   
 
Dietary intake assessment methods. Seventeen different types of dietary 
assessment methods were identified. Only twelve studies (21%) cited validation studies 
for the nutrition assessment method utilised. No study cited validation of the dietary 
assessment tool utilised, in a SMI population. One study reported piloting their FFQ in 
15 people with SMI, however this data was unpublished. A further twenty-two studies 
(38%) utilised recognised acceptable dietary intake assessment measures such as 24-
hour recall, however only 11 studies (50%) reported that dietitians or other trained 
interviewers completed dietary intake assessment and analysed it using nutrition data 
analysis software, and only four studies utilised multiple, non-consecutive recalls. 
Weighed food records, a more objective measure of dietary intake, was utilised for two 
of these studies. In these two studies, one study assessed seven-day dietary intake, 
and the other two-day dietary intake, both assessed by dietitian/nutritionist. One study 
utilised a three-day photographic food record assessed by a dietitian, also considered a 
more objective measure of dietary intake. For the remaining studies for which validity of 
the assessment tool was unclear, fourteen studies (24%) reported the assessment tool 
very broadly, such as ‘standardised questionnaire’ or ‘verbal questions’ and nine 
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studies (16%) report using FFQs without citing validity, or questions taken from 
National Health Surveys. 
 
Dietary outcomes. A wide variety of dietary outcomes were assessed. The 
most common dietary outcome measures were energy intake (N=22), macronutrients 
(carbohydrate, protein, fat) (N=20), individual fatty acids or fat subgroups (N=20), fibre 
(N=16), food groups/categories (N=14), caffeine or coffee intake (N=12), overall dietary 
patterns (N=9), and micronutrients (N=9). One study also reported health (dietary) 
knowledge as a secondary outcome. Dietary outcomes were reported in a range of 
different metrics. For these reasons it was difficult to conduct direct comparisons.  
 
Quality of studies. Thirty-nine studies (67%) received a neutral score, 13 
studies (22%) received a negative score and six studies (11%) received a positive 
score. Key areas of weakness included; (i) lack of concurrent controls, and 
comparability of groups on important confounding factors, (ii) lack of use of 
independent assessors and blinding for data collectors (when concurrent comparator 
groups were used), (iii) measurements not being based on standard, valid and reliable 
methods and procedures (iv) measurements implemented at unclear level of precision, 
and (v) inconsistent measures used across groups. Individual study quality data are 
outlined in Supplementary File 5. 
 
Quantitative Analysis 
In two studies that only reported median averages [46, 50], medians were used as an 
imputed mean, and standard deviations were estimated from the pooled standard 
deviations across all other studies. For the one study that did not report SD for controls 
[54], SD was imputed from a study of similar sample size [42]. 
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 Energy. Seven studies (n=1,448) reported energy intakes for both people with 
SMI and controls [27, 32, 46, 47, 50, 51, 55]. Mean energy intake among individuals 
with SMI was 1,332kJ/day higher than among the control subjects (95% C.I. +487 to 
+2,178kJ/day, p = 0.002), with a moderate effect size for the difference between 
groups [N=7, g=0.463, (95% C.I. 0.159 to 0.767), p = 0.003]. Although there was 
heterogeneity across the study data (Q = 25.7, p < 0.001, I2 = 76.7%), there was no 
evidence of publication bias (p = 0.328 for Egger’s regression test), and the fail-safe N 
was 67 (estimating that 67 unpublished “null” studies would need to exist for the actual 
p value to exceed 0.05). A trim-and-fill analysis did not identify any outliers, and the 
random effects point estimate remained at g = 0.463. These findings were in line with 
the two studies which utilised weighed-food records that found, (i) energy intake was 
significantly higher in the schizophrenia group compared to general population [64], 
and (ii) energy intake increased with the commencement of olanzapine, in line with the 
weight gain observed [35]. 
 
Subgroup analysis found the mean difference in energy intake for the schizophrenia 
spectrum cohorts compared to controls was +1,695kJ/day (95% C.I. 380 to 
3,010kJ/day), p = 0.012, and the mean difference between energy intake in BPD only 
cohorts compared to controls was +827kJ/day (95% C.I. 146 to 1,508kJ/day), p = 
0.017. The between group difference in energy intake for BPD-only and schizophrenia 
spectrum-only cohorts was not statistically significant (Q = 1.32, p = 0.251). These are 
illustrated in Figure 2. 
 
Insert Figure 2 about here 
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Additional Nutrients. Three studies (n=387) reported data able to be pooled 
for meta-analysis for sodium, vitamin B6, vitamin C and zinc [47, 50, 55]. Sodium 
intake was significantly higher in the SMI group [mean difference +332mg, 95% C.I. 
174 to 490mg, Z = 4.121, p < 0.001, I2 = 12%, g = 0.414]. There was no significant 
difference in pooled intakes of vitamin B6, vitamin C and zinc between people with SMI 
and controls (all p > 0.2). See Table 1 for meta-analysis results for energy and nutrient 
intakes. 
 
Insert Table 1 about here 
 
Qualitative Synthesis 
Dietary patterns and diet quality scores were assessed in eight studies and two studies 
respectively. The SMI group was found to have less healthy dietary patterns in eight 
studies [36, 46-49, 58, 76] and females had lower diet quality in one study which 
assessed diet quality [20], and a mean diet score within the ‘unhealthy’ category for the 
other study assessing diet quality [63]. No included study found healthier dietary 
patterns for the SMI group when compared to control or population data. Four studies 
reported a relationship between dietary patterns and SMI; a higher ‘western’ and 
‘modern’ dietary pattern was positively associated, and ‘traditional’ dietary pattern 
negatively associated with BPD [46], a ‘cereal’ dietary pattern (bread, rice, 
confectionary etc.) was positively associated with SCZ while a ‘vegetable’ dietary 
pattern was not [72], and higher energy intake, and lower protein intake, were positively 
associated with general symptom severity in early psychosis in one study [51], while 
life stress was positively associated with increased refined sugar intake in people 
experiencing psychosis but negatively associated with refined sugar intake in both 
high-risk for psychosis and healthy subjects, in the same study. A fourth study in Japan 
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found males who had infrequent intakes of vegetables, mayonnaise, potatoes, soy 
products, seaweed and fish products had more pronounced psychiatric symptoms, 
although this correlation was not found in women [76]. 
 
Fruit and vegetable intake was found to be lower in the SMI group compared to 
controls/population data in three studies [48, 52, 62] and less than country/region- 
specific recommendations in nine studies [26, 34, 39, 41, 43, 52-54, 63], and higher 
compared to the general population in one study [77]. Low intakes, or lower intakes 
than comparison groups, were found for fish [54, 63], and nuts and vegetable oils [20]. 
Large intakes, or higher intakes than comparison groups, were found for carbonated 
beverages [20], sweetened beverages [30], soft drinks [69], cakes and other sweets 
[69], white bread [43], hydrogenated oils [20] and fast-food/takeaway foods [43, 62]. In 
addition, one study found poor diet literacy [41] and one study found difficulties 
obtaining and/or cooking food [48] for people with SMI. 
 
Results for macronutrients and micronutrients were mixed when compared to reference 
groups and recommended intakes, with no clear findings emerging. There were trends 
for studies to find lower mono- and poly-unsaturated fats [24, 28, 29, 55], and higher 
intakes of total and saturated fat [51, 54, 57, 64, 65, 72] and trans fats [55] in the SMI 
groups when compared to a comparator (control or population data). In addition, higher 
sugar intake was found in two studies [57, 72].  
 
Results for fibre intakes were mixed when compared to controls or population data, 
although the SMI group consumed less than national/region recommendations in nine 
studies [24, 29, 42, 44, 47, 50, 54, 65, 68] and adequate in one study [55]. For caffeine 
intake, five studies found higher caffeine intakes, or high caffeine intakes (≥200mg/day)  
  
   16 
to be more frequent, in the SMI group compared to reference group [19, 37, 44, 65, 66] 
and one study found no difference [22]. One study found people with psychosis to have 
a higher frequency of ‘high’ coffee consumption (≥5 cups/day) compared to other 
mental illnesses including depression and alcohol use disorder [75]. Seven studies 
found smokers in the SMI groups to have the highest caffeine intakes [19, 22, 23, 25, 
37, 65, 66]. Differences in reporting of caffeine and caffeinated drinks as outcomes 
meant that data could not be pooled for meta-analysis.  
 
Discussion 
This is the first meta-analysis of dietary intake in people with either psychosis or bipolar 
disorder and showed significantly higher total energy and sodium intakes compared to 
controls. This study also found consistent reports of less healthy dietary patterns 
including low intakes of fruit and vegetables, and high intakes of take-away and other 
convenience foods, and sugar-sweetened beverages. A previous qualitative synthesis 
in schizophrenia and schizoaffective disorder [12] suggested poorer dietary patterns in 
this population. Poorer dietary patterns are not limited to schizophrenia and 
schizoaffective disorder and included all those with a SMI diagnosis, although energy 
intake appears to be highest for those with psychotic disorders. This was also the first 
study to systematically review dietary intake assessment methods and strength of 
reporting, fulfilling a need to improve scientific rigour in this area.  
 
The strongest evidence was found for higher energy and sodium intakes in SMI 
populations, with statistically significant differences compared to control samples 
(+1,332kJ/day and +322mg/day higher in SMI respectively) when pooled intakes 
obtained from validated assessment tools were compared with matched controls. 
These findings are consistent with the two studies utilising weighed food records 
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(considered the most accurate method) which found; (i) a significant increase in caloric 
intake coinciding with weight gain [35], and (ii) SCZ group consumed more energy, 
sugar and fat compared to the general population [64]. Both meta-analyses revealed 
moderate effect sizes (g = 0.46 and g = 0.41 respectively), and are of considerable 
clinical relevance, particularly an increased energy intake of 1,332kJ per day, given 
that, i) the general population is already over-consuming energy [78] and salt [79], and 
ii) this is compounded with high levels of sedentary behaviour [80], and low 
cardiorespiratory fitness [81], which helps to explain the alarming rates of obesity, 
metabolic syndrome, diabetes, cardiovascular disease and premature mortality in 
people with SMI [3]. The weight change dynamics paradigm of Hall and co-workers’ 
[82] predicts that every 100kJ intake excess will have an eventual body weight change 
of 1kg. Applied to the findings from this study, someone with SMI would weigh on 
average 13kg more than the general population (mean 8kg and 17kg in the BPD and 
SCZ groups respectively) from dietary factors alone.  
 
Increased energy and sodium intakes are likely explained by increased hunger and 
preference for ‘discretionary foods’ such as sweetened beverages and convenience 
foods, which are high in sugar, salt and fat (and therefore energy) and low in beneficial 
nutrients such as fibre, vitamins and minerals. Reasons for increases in appetite 
remain to be clarified. A wide variety of neuroreceptor and neuroendocrine factors 
regulate eating behaviour and appetite in SMI [83]. Dopamine, serotonin, muscarinic 
and histamine receptors have all been implicated in antipsychotic-induced increases in 
hunger, with drugs with high affinity for 5HT2c and muscarinic receptors associated with 
the greatest risk of weight gain [84, 85]. Compounded with the lower levels of physical 
activity among people with SMI [80], this helps to explain the stark difference in weight 
and BMI status between people with SMI and the general population [86]. 
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Intakes of the micronutrients vitamin B6, vitamin C and zinc were not significantly 
different from control in this study, although these analyses were limited to the few 
studies that included such data. Given a previous analysis found blood levels of 
micronutrients were significantly lower in SMI compared to healthy controls [87], more 
well-designed dietary intake studies should investigate micronutrients, particularly 
those with a close relationship to mental health, such as folate.  
 
Strengths and limitations 
The search strategy was limited to articles written in English and therefore articles 
written in another language were not reviewed. In addition, grey literature was not 
searched for this review. The study aimed to focus on naturalistic cohort data of real 
world patients dietary consumption such that the results would reflect clinical reality, 
hence the inclusion of cohort/cross sectional studies, and the exclusion of RCT data. 
 
Attempts were made to disentangle the effects of antipsychotic and mood-stabilising 
medication, however due to insufficient reporting, limited conclusions could be made 
from this review. Given the differing effects on metabolic health of antipsychotics and 
mood-stabilising medications, more research is needed to explore the specific effects 
of individual medications on dietary intake and eating behaviours. 
 
Qualitative synthesis found a large range of dietary assessment and analysis methods 
and outcomes were employed, a clear challenge for interpreting dietary intake. A large 
proportion (37%) either used an unvalidated tool or did not report whether the tool had 
undergone validation, which limits generalisability of any findings. Those studies which 
utilised validated assessment or recognised, acceptable methods were often not 
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specific to mental health populations; that is, it is unknown if the tools perform 
accurately or individuals with mental health diagnoses can accurately report on dietary 
intake. However, the two studies utilising weighed food records and one study utilising 
a photographic food diary, more objective measures of dietary intake, found results in 
line with the results obtained in the current review. The overall strength of reporting in 
many studies was also limited, with the majority considered to be neutral, i.e. neither 
strong nor weak (N=40).  
 
The dietary intake methods utilised in studies included in this meta-analysis were 
based on self-report, so may reflect subjective bias. This review comprehensively and 
systematically reviewed all published studies, providing a best-guess insight into 
dietary intake in people with SMI. Misreporting is a common issue in the general 
population, with an average energy underreporting of approximately 20%, and higher in 
people who are obese (~30%). Given that people with SMI commonly experience 
additional barriers, including cognitive impairment, lack of motivation and poor memory, 
misreporting could be expected to be more common, and to have a larger impact, in 
this population, suggesting the findings on energy intake may be an underestimation. 
Comparisons against population data can be misleading as the population data can be 
captured years or even decades earlier, are generally unmatched to the target group 
and may have utilized a different nutrition assessment method to the target group. 
These provide potential explanations for conflicting results, which have been reported 
[47, 74].  
 
Results from this review suggest that no dietary assessment method or tool has been 
thoroughly validated in SMI. There is a clear need for subjective measures of dietary 
assessment to be compared with objective measures, such as biomarkers, to assess 
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the accuracy of self-report measures in people with SMI. Biomarkers, such as 
carotenoids which are reflective of fruit and vegetable intake [88], or doubly-labelled 
water which is reflective of total energy intake [89], are validated specific measures of 
dietary intake in the general population. Whilst direct relationships between diet and 
objective biomarkers likely also exist in mental illness, consideration of certain factors 
is needed when interpreting results. For example, inflammation associated with mental 
illness may reduce the levels of these biomarkers. Given cognitive impairment, poor 
memory, motivation difficulties and potential recall bias, those assessing dietary intake 
need expertise or training in dietary assessment method selection and implementation, 
to ensure appropriate use of particular methods. Given short-term, ‘snapshot’ 
assessments of dietary intake were commonly used (such as the use of 24 hour 
recalls), long-term dietary intake in SMI may require further investigation. Meta-
analyses in this review were also limited due to the range of metrics used to report 
outcomes, placing greater importance on complementary qualitative synthesis. 
 
As the pooled prevalence of recovery in first-episode of psychosis (FEP) is 38% [90], 
and weight-gain and metabolic decline are most rapid in FEP in the earlier stages of 
psychotropic medication treatment [7], it was deemed imperative to review studies that 
included clinician-diagnosed FEP. The four identified studies in FEP found 
unfavourable dietary intakes [59, 60, 62, 74], in line with the results for established, 
enduring SMI. This is particularly important, since increased food intake and the 
majority of associated weight gain is believed to begin following initiation of 
antipsychotic treatment [11, 91]. Furthermore, FEP has been identified as a ‘critical 
period’ for targeting lifestyle behaviours in order to prevent obesity and metabolic 
dysfunction from arising later in life [92].  
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There was limited information obtained from the systematic review for the impact of diet 
on brain health and mental illness symptomatology however evidence in this area is 
growing. There appears to be a bidirectional relationship between diet quality and 
depression [93], with emerging RCT evidence finding improvements in diet quality 
correlate with improvements in depressive symptoms [94, 95]. Additionally, dietary 
intake appears to be a factor in brain health in humans, which may be of particular 
relevance given the neurodegeneration involved with SMI. High blood sugar and 
western diet, which is high in processed, non-nutritious foods, and low in commonly 
recommended foods of a healthy diet, are associated with smaller hippocampal volume 
[96, 97]. Further, a meta-analysis has also demonstrated the potential preventative 
action of diet on the development of a series of brain ailments including cognitive 
impairment (8 studies, RR=0.60, 95% CI 0.43-0.83) and depression (9 studies, 
RR=0.68, 95% CI 0.54-0.86) [98].  
 
Future recommendations 
Future recommendations include; (i) use of technology to assist people with mental 
illness to record/remember foods consumed, (ii) use of food models/images and a food 
checklist to assist people with remembering food and beverage items and to estimate 
portion sizes, (iii) utilising a trained interviewer or diet expert such as dietitian, (iv) 
utilising an online dietary assessment primer or published review [99] to choose the 
most appropriate assessment method, and (v) utilising relevant guidelines such as 
Strengthening the Reporting of Observational Studies in Epidemiology – nutritional 
epidemiology (STROBE-nut) [100] to enhance reporting of dietary intake studies. 
 
Additionally, further research should be dedicated to the following areas; (i) 
comprehensive evaluation of dietary intake relative to psychotropic medications, (ii) 
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dietary intake in the early stages of illness as targets for preventative intervention, (iii) 
dietary intake pre-illness onset to observe if unhealthy dietary intake precedes illness 
onset i.e. at-risk mental state, and whether any dietary factors may indicate the onset 
of illness, (iv) the effect of dietary patterns on psychiatric symptoms, and characteristic 
of illness such as cognitive impairment, in people with SMI, and (v) evaluating the 
validity and reliability of dietary assessment methodologies in people with SMI to 
determine appropriate methods for future use, or facilitate the development of new 
methods. Validation should be completed using energy equations to determine 
accuracy, use of the method of trials to establish believability, and where possible use 
objective biomarkers to validate.   
 
Overall, the findings of this study are clinically important, as poor dietary intake, 
particularly low intakes of fruit and vegetables, and high intakes of fast food and other 
convenience foods, and sweetened beverages, may lead to greater risk for future 
cardiometabolic illness. Dietary interventions should be a standard part of care for 
people with SMI, to help mitigate the physical health disparities in this population 
compared to the wider population. 
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Table 1. Meta-analysis of dietary energy and nutrient intakes. 
 
Comparison Number 
studies 
Hedges-G Lower limit Upper limit Z-value P-value I2 Mean 
difference 
Lower Limit Upper limit Z-value P-value I2 
Energy (kJ) 7 0.463 0.159 0.767 2.986 0.003 77 1332 487 2178 3.089 0.002 76 
Sodium (mg) 3 0.414 0.181 0.646 3.488 <0.001 12 322 174 490 4.121 <0.001 0 
Vitamin B6  3 0.484 -0.532 1.499 0.933 0.351 95 0.4 -0.4 1.2 0.999 0.318 96 
Vitamin C (mg) 3 0.132 -0.530 0.794 0.391 0.696 88 8.7 -47.0 64.4 0.305 0.760 86 
Zinc (mg) 3 0.369 -0.233 0.971 1.202 0.229 85 1.6 -1.4 4.5 1.038 0.299 85 
 
 
 
Figure 1. PRISMA Flowchart 
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Figure 2. Meta-analysis of energy intake in bipolar disorder and schizophrenia. 
 
 
 
 
 
 Group by
Status
Comparison Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value Total
Bipolar Disorder Energy (kJ) Chang, 2017 796.000 422.684 178662.170 -32.446 1624.446 1.883 0.060 166
Bipolar Disorder Energy (kJ) Evans, 2014 288.000 541.768 293512.737 -773.846 1349.846 0.532 0.595 91
Bipolar Disorder Energy (kJ) Jacka, 2011 1691.000 688.646 474232.978 341.279 3040.721 2.456 0.014 714
Bipolar Disorder 826.998 347.507 120760.941 145.897 1508.098 2.380 0.017 971
Schizophrenia Energy (kJ) Jahrami, 2017 2273.800 342.886 117570.467 1601.757 2945.843 6.631 0.000 240
 Schizophrenia Energy (kJ) Konarzewska, 2014 -500.589 700.776 491086.341 -1874.084 872.906 -0.714 0.475 86
Schizophrenia Energy (kJ) Manzanares, 2014 2461.000 582.928 339805.138 1318.482 3603.518 4.222 0.000 90
Schizophrenia Energy (kJ) Nunes, 2014 2565.000 1083.224 1173373.184 441.921 4688.079 2.368 0.018 50
Schizophrenia 1695.052 670.884 450085.577 380.143 3009.960 2.527 0.012 466
-4000.00 -2000.00 0.00 2000.00 4000.00
Higher in Controls Higher in Patients
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participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  5,6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
6 
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Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
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7 
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for obtaining and confirming data from investigators.  
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Risk of bias in individual 
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DISCUSSION   
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Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
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Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
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12 Use of hand searching (eg, reference lists of obtained articles) 5 
13 List of citations located and those excluded, including justification 9-10, Fig 1, Table 1 
14 Method of addressing articles published in languages other than English - 
15 Method of handling abstracts and unpublished studies 6 
16 Description of any contact with authors - 
Reporting of methods should include 
17 Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested 5-6 
18 Rationale for the selection and coding of data (eg, sound clinical principles or convenience) 5-6 
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20 Assessment of confounding (eg, comparability of cases and controls in studies where appropriate) 7-8 
21 Assessment of study quality, including blinding of quality assessors, stratification or regression on possible predictors of study results 6-7 
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23 
Description of statistical methods (eg, complete description of fixed or random effects 
models, justification of whether the chosen models account for predictors of study 
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replicated 
7-8 
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Tables 1-2, 
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Suppl 1-3 
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25 Graphic summarizing individual study estimates and overall estimate Table 2, Fig 2 
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Supplementary File 4. Characteristics of included studies 
 
Study Design Population studied Control or 
Comparative Group 
Nutrition Ax Method Validated or 
recognised measure 
 
Outcomes Study 
Quality 
Score^ 
Main Findings 
Adolfo et al, 2009  
(USA) 
Cross-cue 
reactivity 
SCZ, SAD 
80% receiving SGAs  
Outpatients 
n=15 
 
Control 
n=18 
Caffeine use history. 
Assessor not described 
Unknown Caffeine (mg)  SMI group had higher intake of caffeine (mg) and caffeinated 
drinks.  
Statistical trend for smokers to have greater caffeine urges. 
Amani et al. 2007  
(Iran) 
 
 
Cross-sectional SCZ 
Medications not described 
Inpatients 
n=30 
Control 
n=30 
Semi-quantitative FFQ 
Assessed by nutrition students 
Unknown Diet quality (score),  
Food groups (% of people 
consuming) 
 People with a SMI consumed more carbonated drinks & 
hydrogenated oils & ate less nuts & vegetable oils.  
Females with SMI had lower diet quality compared with 
controls.  
Archie et al. 2007 
(Canada) 
 
Cross-sectional SMI 
100% prescribed APMs 
(70% SGAs, 15% FGAs, 
15% combination) 
Outpatients 
n=101 
 
General population 
data 
 
Dietary Fat Screener & Fruit & Vegetable 
& Fibre Screener 
Assessor not described 
Correlates with 100-
item FFQ – 
recognized acceptable 
measure 
Fat (g),  
Saturated fat (g),  
Fibre (g),  
Fruit (servings/day),  
Vegetables (servings/day) 
+ People with SMI had a high fat, and saturated fat, intake. 
Intake of fruit & vegetables was higher in the SMI group 
compared to general population data. 
 
 
Arrojo-Romero et al. 
2015 
(Spain) 
Cross-sectional 
(4 arm) 
SCZ, SAD 
Medications reported in 
chlorpromazine equivalents 
Inpatients 
n=145 
 
Other SMI 
Medications reported in 
chlorpromazine equivalents 
Inpatients 
n=64 
 
Control 
n=290 
Standardised questionnaire 
Assessed by physician 
Unknown Caffeine (mg/day)  Frequency of caffeine use in SCZ inpatients was significantly 
higher than in SCZ outpatients.  
Frequency of high caffeine users among caffeine users was 
significantly higher in SCZ outpatients compared to SCZ 
inpatients.  
Smoking was significantly associated with caffeine.  
No significant difference in caffeine intake between people 
with SCZ and controls. 
Baethge et al. 2009 
(Germany) 
Longitudinal BPD 
Medications not described 
Outpatients 
n=352 
 
None Estimated daily coffee consumption. 
Assessed by study investigator.  
Unknown Caffeine (cups/day)  Mean 3 (+/-2) cups of coffee per day. 
Coffee intake higher in smokers.  
Coffee intake associated with suicidal ideation. 
 
Bly et al. 2014 
(USA) 
Cross-sectional SCZ 
100% prescribed SGAs 
Outpatients 
n=143 
 
BPD 
100% prescribed SGAs  
Outpatients 
n=116 
Matched population 
data 
n=259 
24 hour recall (x3 within 10 days) 
Assessed by dietitian. 
Analysed by the Nutrition Data Systems 
for Research software 
Recognised 
acceptable measure 
Energy (kcal/day), 
Macronutrients (kcal/day),  
Fibre (g/day),  
EFAs (g/day) 
 SMI group had lower energy & omega-6 to omega-3 ratio & 
higher fibre intake compared to population data.  
BPD group has lower energy & mono- & polyunsaturated fat & 
higher fibre intake compared to population data. 
Bobes et al. 2010 
(Spain) 
 
Cross-sectional 
 
SCZ 
100% prescribed APMs 
Outpatients 
n=1704 
None Series of verbal questions. 
Assessor not described 
Unknown Caffeine (cups/day),  
Salt (yes or no to meals),  
Fibre (freq of intake),  
Low caloric diet (freq of intake),  
Saturated fat (freq of intake) 
 
 Smokers more likely to consume daily caffeine (1 or more 
cups per day), & less likely to avoid salt & saturated fat, or to 
follow a high fibre or low caloric diet 
Brown et al. 1999 
(UK) 
Cross-sectional SCZ 
91% prescribed 
General population 
data 
DINE 
Assessor not described  
Validated for a study 
of health educators in 
Fat (g),  
Unsaturated fat (g),  
 People with SCZ had diets higher fat and lower in fibre than 
the general population.  
 psychotropic medication 
Outpatients 
n=102 
 
general practice 
attenders 
Fibre (g),  
Fruit (portions/day),  
Vegetables (portions/day) 
No SMI participants ate the recommended 5 portions of fruit or 
vegetables per day. 
 
 
Chang et al. 2017 
(USA) 
 
Cross-sectional BPD 
63% prescribed MS 
52% prescribed SGAs 
Outpatients 
n=91 
 
Control 
n=75 
7 day diet record 
Assessed by dietitian 
Analysed using Nutrition Data System for 
Research software 2011 
 
Recognised 
acceptable measure 
Energy (kcal),  
Linoleic acid (g) 
+ Energy intake higher in BPD group compared to controls 
(statistical trend) 
Non-significant difference in linoleic acid intake between 
groups 
Clayton et al. 2008 
(Australia) 
 
Cross-sectional BPD 
100% prescribed MS 
Outpatients 
n=15 
Control 
n=15 
FFQ 
Assessor not described 
Unknown EFAs (mg/day)  BPD had significantly lower intake of EFAs (except DPA) 
compared to controls 
Ellingrod et al. 2011 
(USA) 
 
Cross-sectional SCZ, SAD, SCZF 
100% prescribed APMs 
(88% SGAs, 12% FGAs) 
26% prescribed MS 
Setting not described 
n=63 
APM group compared 
to no APM group 
24 hour recall (x3 within study period). 
Assessor not described 
Analysed by the Nutrition Data Systems 
for Research software 
 
Recognised 
acceptable method 
Energy (kcals/day), 
Macronutrients (g/day),  
FA subgroups (g/day),  
Fibre (g/day) 
 Statistical trend for SMI group to have lower PUFA: SFA ratio.  
Elmslie et al. 2001 
(New Zealand) 
 
Cross-sectional BPD 
87% prescribed 
pharmacotherapy 
Outpatients 
n=89 
Matched population 
data 
n=445 
24 hour recall & 4-day estimated diet 
record. 
Assessor not described 
Analysed by Diet Cruncher software 
 
Recognised 
acceptable measure 
Energy (kJ) 
Macronutrients (g) 
 BPD group consumed more total fluid & sweetened drinks.  
Females with BPD consumed more energy than reference 
group. 
 
Evans et al. 2014 
(USA) 
 
Cross-sectional BPD 
63% prescribed MS 
52% prescribed SGAs 
Outpatients 
n=47 
 
Control 
n=44 
7 day diet record 
Assessed by dietitian 
Analysed using Nutrition Data System for 
Research software 2011 
 
Recognised 
acceptable measure 
Energy (kCal),  
EFA (g),  
Selenium (mcg) 
+ Energy, SFA, eicosanoic & docosanoic FA intake higher in 
BPD compared to controls. 
Intake of selenium, EPA, DHA, DPA & AA lower in BPD group 
compared to controls. 
Evans et al. 2015 
(USA) 
 
Cross-sectional BPD 
63% prescribed MS 
48% prescribed SGAs 
Outpatients 
n=56 
 
Control 
n=46 
7 day diet record 
Assessed by dietitian 
Analysed using Nutrition Data System for 
Research software 2011 
 
Recognised 
acceptable measure 
Macronutrients (% total energy), 
EFA (% total FA),  
 
+ Intake of EPA, DHA, AA lower in BPD group compared to 
controls. 
No difference in intake of macronutrients as % of energy 
intake, SFA, PUFA, MUFA, LA or ALA 
 
Fawzi et al. 2015 
(Egypt) 
Cohort SCZ 
100% prescribed APM 
(58% FGA, 17% SGA, 25% 
combination) 
Outpatients 
n=100 
 
None 24 hour recall (x3 within study period) 
Assessor not described 
Analysed using program based on 
Egyptian Food Composition Tables 
Recognised 
acceptable measure 
Energy (kCal),  
Macronutrients (g) 
 Mean energy, protein, CHO & fat intake slightly higher in SCZ 
group with metabolic syndrome compared to SCZ group 
without metabolic syndrome. 
 
Fusar-Poli et al. 2009 
(Italy) 
Cross-sectional SMI 
Medications not described 
Outpatients 
n=123 
General population 
data 
 
Questionnaire 
Assessor not described 
Unknown Fruit, vegetables (no. per day)   Low fruit and vegetable intake. 
Gothelf et al. 2002 
(Israel) 
 
Cohort SCZ 
100% prescribed OLZ 
Inpatients 
n=10 
None Weighed food record  
(2 consecutive days) 
Assessed by dietitian 
Recognised 
acceptable measure  
Energy (kCal)  People receiving OLZ had a significant increase in caloric 
intake coinciding with weight gain. 
Gupta et al. 2009 
(UK) 
Cross-sectional SCZ 
Medication not described 
Residential care 
General population 
data 
FFQ (past 7 days), responses cross-
checked with staff. 
Assessor not described 
Unknown  ‘Healthy’ and ‘unhealthy’ food 
categories 
 People in both high level and medium level care made more 
unhealthy food choices. Provision of healthy food options may 
not automatically equate to healthier diets. 
n=21  
(low care) 
n=41  
(high care) 
Gurpegui et al. 2004 
(Spain) 
 
Cross-sectional SCZ 
94% taking APMs  
(75% FGAs, 25% SGAs) 
Outpatients 
n=250 
 
None Self-reported alcohol & caffeine intake. 
Assessor not described 
Unknown  Caffeine (mg/kg/day),  
 
- Caffeine associated with smoking and alcohol intake. 
No clear association between caffeine intake and APM or 
symptom severity. 
Gurpegui et al. 2006 
(Spain) 
 
Case control SCZ 
94% taking APMs  
(75% FGAs, 25% SGAs) 
Outpatients 
n=250 
 
Control 
n=290 
Self-reported alcohol & caffeine intake. 
Assessor not described 
Unknown Caffeine (mg/day),  
 
 Amongst caffeine users, high caffeine intake more frequent in 
SMI compared to controls.  
Hahn et al. 2014 
(Australia) 
 
Cross-sectional SMI 
Medications not described 
Setting not described 
n=1,286 
 
None Semi-structured interview using 
standardised questionnaire. 
Assessor not described 
Unknown  Food intake (g),  
Difficulty purchasing food 
(shortage of $) 
 74% people with psychosis ate <4 servings of fruit & 
vegetables combined daily.  
Unhealthy dietary intake associated with other detrimental 
lifestyle factors. 
Hamera et al. 1995 
(USA) 
Cohort SCZ, SAD 
100% prescribed APM 
(52.9% oral, 29.4% LAI. 
17.6% combination) 
Outpatients 
n=17 
 
None Substance use checklist  
(previous 24 hours) 
Assessor not described 
Unknown Caffeine (cups) 
 
- No association between psychosis symptom severity and 
caffeine, but caffeine intake increased with increased tension 
& depression.  
Hardy et al. 2012 
(UK) 
 
Cross-sectional SCZ 
100% prescribed APM 
(75% SGA, 12.5% FGA, 
12.5% combination) 
Outpatients 
n=8 
 
None Food diary (1 week). 
Assessed by study investigator. 
Recognised 
acceptable measure 
Dietary pattern (qualitative data) - People with SCZ had low overall consumption and variety of 
consumption of fruit and vegetables with a high consumption 
of convenience and ready-to-eat meals.  
Poor diet literacy in people with SCZ. 
Haruyuki et al. 2015 
(Japan) 
 
Cross-sectional SCZ 
Medication not described 
Outpatients 
n=51 
 
General population 
data 
Photographic 3-day food record. 
Assessed by dietitian. 
Recognised 
acceptable measure 
Energy (kcal),  
Macronutrients (g), 
Micronutrients (mg/µg),  
Fibre (g) 
 SCZ patients had higher intake of energy, CHO, fat, calcium, 
phosphorus and sodium compared to general population. 
 
 
Heald et al. 2017 
(UK) 
Cross-sectional 
 
SCZ, SAD 
100% neuroleptics 
(54% oral SGAs, 35% 
depot APM, 11% MS) 
Outpatients 
n=32 
 
None Dietary questionnaire. 
Assessor not described. 
Recognised 
acceptable measure 
Food categories (portions, days 
eaten) 
 Most participants were not eating fruit (84%) and vegetables 
(75%) on >5 days/week.  
Majority chose white bread. 62.5% had takeaway foods within 
the last week. 
Henderson et al. 2005 
(USA) 
 
Cross-sectional SCZ, SAD 
100% prescribed SGAs 
Outpatients 
n=36 
 
None 4-day food record 
Assessor not described 
Analysed through Minnesota Nutrient 
Data System 
Recognised 
acceptable measure 
Energy (kcal),  
Macronutrients (% EI),  
Sugars (g),  
 
  
 Mean energy intake by APM in descending order was 
olanzapine (2,583.6kcal/day), clozapine (2,199kcal/day), 
risperidone (1,921kcal/day), (p=0.33, n=12 in each group). 
Henderson et al. 2006 
(USA) 
Cross-sectional SCZ, SAD 
98% prescribed SGAs 
Outpatients 
n=88 
Matched population 
data 
n=723 
4-day dietary record & block FFQ. 
Assessed by trained dietary interviewers. 
Analysed by Minnesota Nutrient 
Database. 
Recognised 
acceptable measure 
 
FFQ validated against 
24-hr diet recall, 3-day 
diet record & serum 
carotenoids. 
Energy (kcal)  
Macronutrients (g, % EI) 
Fat subgroups (g, % EI),  
Micronutrients (mg, mcg),  
Fibre (g),  
Caffeine (mg),  
 
 SMI group consumed less energy, CHO, protein, fat, fibre, 
sodium & folate but more caffeine than the comparison group. 
 
Jacka et al. 2011 
(Australia) 
 
Cross-sectional BPD 
Medications not described 
Setting not described 
n=23 
Control 
n=691 
Dietary Questionnaire for 
Epidemiological Studies. 
Assessor not described. 
Validated against 
weighted food records 
in healthy Australian-, 
Greek- and Italian-
born adults living in 
Australia. 
 
Energy (kJ),  
Glycaemic load,  
Dietary patterns: ‘western’, 
‘modern’, & ‘traditional’  
 
+ BPD group had higher glycaemic load, & higher scores on the 
‘western’ & ‘modern’ diet scores.  
Higher ‘western’ & ‘modern’ score positively associated, & 
‘traditional’ score negatively associated, with BPD. 
Jahrami et al. 2017 
(Bahrain) 
Case control SCZ, SAD, SCZF 
Medications not described 
Outpatients 
n=120 
Control 
n=120 
 
FFQ (past 1 month). 
Assessor not described. 
Pilot study with 15 
patients with SCZ 
(unpublished data) 
Energy (kcal),  
Macronutrients (g),  
Fat subgroups (g),  
Micronutrients (mg),  
Fibre (g),  
Caffeine (mg),  
Individual foods (g/ml) 
 
+ SMI group had excessive dietary intakes (energy, 
macronutrients, high energy/nutrient poor foods) when 
compared to controls. 
Kilbourne et al. 2007 
(USA) 
Cross-sectional SCZ 
80% prescribed APM 
Setting not described 
n=1720 
 
BPD 
32% prescribed APM 
Setting not described 
n=1925 
Control 
n=3065 
Questionnaire (3 nutrition & 3 eating 
habits questions). 
Assessor not described. 
Unknown Eating habits,  
Fruit juice (# servings),  
Fruit (# servings),  
Vegetables (# servings),  
 BPD & SCZ groups more likely to report suboptimal eating 
behaviours and report difficulties obtaining or cooking food. 
Killan et al. 2006 
(Germany) 
Cross-sectional SMI 
Medications not described 
Inpatients 
n=363 
General population 
data n=7124 
Standardised questionnaire. 
Assessor not described. 
Unknown  ‘Unhealthy nutrition behaviour’ 
(based on consumption of fruit, 
vegetables, salty snacks, 
sweets, fast food & ready-to-eat 
meals – not quantified)),  
 
 SMI group had higher levels of unhealthy lifestyle practices 
including ‘unhealthy nutrition behaviour’.  
Konarzewska et al. 
2014 
(Poland) 
 
Cross-sectional SCZ 
100% prescribed APM 
Setting not described 
n=52 
 
Control 
n=45 
24-hour recall (3 consecutive days using 
food images) 
Assessor not described. 
Analysed by Diet 5 software 
Recognised 
acceptable measure 
Energy (kcal),  
Macronutrients (g), 
Micronutrients (mg & µg),  
Fibre (mg) 
 Male SCZ group reported lower energy, glucose, protein and 
fibre, vitamins B2+C, & minerals zinc, magnesium, iron, 
copper, calcium compared to control. While D3, folic acid, 
calcium & magnesium did not meet recommended intakes.  
Female SCZ group reported higher saturated fat intakes. D3, 
C, folic acid, calcium and magnesium did not meet 
requirements. 
Manzaneres et al. 
2014 
(Spain) 
 
Cross-sectional SMI 
86% prescribed APM 
Outpatients 
n=65 
Control 
n=25 
24-hour recall. 
Assessed by dietitian             
Analysed by CESNID, Barcelona 
University software 
 
Recognised 
acceptable measure 
Energy (kcal) 
Macronutrients (%EI)  
Refined sugar (%EI) 
Sodium (mg) 
 SMI & high risk for psychoses groups had higher energy & 
saturated fat (% of total energy) intakes compared to controls. 
Symptom severity positively associated with energy intake.  
 
McCreadie et al. 2003 
(Scotland) 
 
Cross-sectional SCZ 
94% prescribed APM  
Outpatients 
n=102 
General population 
data 
FFQ (part of Scottish Health Survey, 
modelled on the Health Survey for 
England). 
Assessed by research nurse 
Analysis program not required 
Unknown  Selected foods: fruit, vegetables, 
legumes, oily fish, cereal, 
wholemeal bread (% of intake) 
 Mean weekly fruit & vegetables consumed by SCZ group was 
16 (recommended intake is 35 per week). More males in SCZ 
group consumed inadequate fruit, vegetables, milk, potatoes & 
pulses compared to general population.  
More females with SCZ consumed inadequate milk & potatoes 
compared to general population. 
Mucheru et al. 2017 
(Australia) 
Cross-sectional SMI 
Medications not described 
Outpatients 
n=221 
 
None Short Diet Questions derived from 1995 
National Nutrition Survey. 
Assessor not described. 
Analysis program not required 
Unknown Fruit, vegetables, breakfast 
consumption, meal frequency 
(frequency of intake)  
 Most participants did not meet recommendations for 
vegetables (86.9%) or fruits (70.6%).  
Average number of meals per day was 3.72, breakfast was 
consumed on average 4.27 times per week.  
Nenke et al. 2015 
(Australia) 
Cross-sectional SMI 
85% prescribed APM 
34% prescribed MS 
General population 
data 
Dietary Questionnaire for 
Epidemiological Studies. 
Assessed by trained researcher 
Validated against 
weighted food records 
in healthy Australian-, 
Energy (kJ)  
Macronutrients (g)  
Micronutrients (mg/ug)  
 SMI group consumed more fat and less fibre and vitamin E 
compared to general population.  
SMI group did not achieve RDIs for fruit & vegetables (98%), 
Setting not described 
n=184 
Analysed using nutrient table for use in 
Australia (NUTTAB95) database 
Greek- and Italian-
born adults living in 
Australia. 
 
Fibre (g) 
Selected foods (g) 
fibre (89%), fish (61%), magnesium (73%) & folate (86%) and 
58% exceeded RDIs of saturated fat and sodium. 
Noguchi et al. 2013 
(Japan)  
 
Cross-sectional Bipolar Depression 
Medications not described 
Outpatients  
n=75 
 
Unipolar Depression 
Medications not described 
Outpatients 
n=91 
  
None Brief self-administered diet history 
questionnaire (BDHQ). 
Assessor not described. 
Analysed by a computer algorithm using 
the Standard Tables of Food 
Composition in Japan. 
 
Validated against 16-
day diet records in 
Japanese adults. 
Dietary patterns: ‘plant foods & 
fish products’, ‘fish’ & 
‘western/meat’  
Energy (kcal) 
Macronutrients (%EI) 
EFAs (%EI) 
Micronutrients (mg, ug/1000kcal) 
 No difference in energy (kJ), nutrient intakes or dietary pattern 
scores between bipolar depression and unipolar depression.  
In men, psychiatric symptoms more pronounced with 
infrequent intakes of vegetables, mayonnaise, potatoes, soy 
products, seaweed and fish products. 
No correlations between dietary pattern scores and symptom 
scores in women. 
Nunes et al. 2014 
(Brazil) 
 
Case control SCZ 
100% prescribed APM 
(68% SGAs, 28% FGAs, 
4% combination) 
Outpatients 
n=25 
 
Control 
n=25 
FFQ (previous 1 month) 
Assessor not described. 
Analysed by NUTRIBASE Software 
 
Validated against two-
consecutive 24hr 
recalls in a Brazilian 
adult sample  
Energy (kcal) 
Macronutrients (%EI) 
Fat subgroups (g/1000kcal, %EI)  
Micronutrients (mg, ug/1000kcal) 
Fibre (g/1000kcal) 
 
 SCZ group had higher intake of energy, energy per kg of body 
weight, % of CHO & TFAs but lower intakes of other types of 
fat, phytosterols & vitamin A compared to controls. 
Osborn et al. 2007 
(UK) 
 
Cross-sectional SMI 
74% prescribed APM   
(64% SGAs, 35% LAI) 
Outpatients 
n=74 
 
Control 
n=148 
DINE 
Assessed by a ‘rater’ 
Analysis program not required 
Validated against a 4-
day diet record in 206 
factory workers in the 
UK. 
Fat, saturated fat, fibre (score) 
Health/dietary knowledge (score) 
 SMI group had lower fibre and higher saturated fat diets 
compared to controls.  
SMI group had lower knowledge on the health benefits of diet 
on cardiovascular risk. 
 
Ratliff et al. 2012 
(USA) 
Cross-sectional SCZ, SAD 
100% prescribed APM 
(69% SGAs, FGAs 31%) 
Outpatients 
n=130 
 
Matched population 
data 
n=250 
24-hour recall (using food models) 
Assessed by trained personnel. 
Analysis program not described 
 
Recognised 
acceptable measure. 
Energy (kcal) 
Macronutrients (g) 
Sodium (mg) 
Caffeine (mg) 
 
 SMI group consumed higher sugar, fat, saturated fat & protein 
compared to controls.  
Both groups exceeded sodium upper limits. 
 
Roick et al. 2007 
(Germany) 
 
Cross-sectional SCZ 
60% prescribed SGAs 
Inpatients 
n=194 
 
General population 
data 
n=2,419 
Eating & drinking section of German 
national health survey. 
Assessor not described. 
Analysis program not required 
Unknown Eating & drinking habits, dietary 
choices 
- SCZ group more frequently consumed instant meals, calorie-
reduced food & supper snacks, and less frequently consumed 
breakfast & healthy groceries compared to general population.  
Ryan et al. 2003 
(UK) 
 
 
Cross-sectional FEP 
Medication Naïve 
Inpatients 
n=26 
Control 
n=26 
DINE 
Assessor not described 
Analysis program not required 
Validated against a 4-
day diet record in 206 
factory workers in the 
UK. 
Monounsaturated fat, saturated 
fat, fibre (score) 
 FEP group consumed more saturated fat compared to 
controls. 
No difference between groups for fibre and monounsaturated 
fat intakes 
 
Ryan et al. 2004 
(UK) 
 
Cohort FEP 
Medication Naïve  
Inpatients 
n=19 
 
Control 
n=19 
DINE 
Assessor not described. 
Analysis program not required 
Validated against a 4-
day diet record in 206 
factory workers in the 
UK. 
 
Monounsaturated fat, saturated 
fat, fibre (score) 
+ FEP group consumed more saturated fat and less fibre 
compared to controls. 
Samele et al. 2007 
(UK) 
 
Case control FEP 
89% prescribed 
psychotropic medication 
Mixed settings 
n=89 
 
Control 
n=89 
Health & lifestyle questionnaire (includes 
FFQ). 
Assessed by study researcher 
Analysis program not required 
 
Unknown ‘High-fat/fast-food diet’, ‘high in 
fruit & vegetables diet’ 
 FEP group more likely to consume high fat, fast food and less 
likely to consume fruit and vegetables.  
 
Saarni et al. 2009 
(Finland) 
 
Cross-sectional SMI 
APM prescription ranges: 
69% in SCZ, 35% in ONP, 
32% in affective psychosis 
Setting not described 
n=208 
General population 
data (Health 2000 
study) 
Standardised dietary questions from 
Finnish Health Examination Survey 
Assessor not described. 
Analysis program not required. 
 
Unknown Healthfulness of diet (based on 
vegetable & saturated fat intake) 
 
- No significant difference in diet healthfulness between SMI 
group and population data. 
 
Simonelli-Munoz et al. 
2012 
(Spain) 
 
Cross-sectional SCZ, SAD, SCZF 
100% prescribed APM 
(64% SGAs, 4% FGAs, 
32% combination) 
Outpatients 
n=159 
 
None Quality of dietary habits questionnaire. 
Assessed by nurse. 
Analysis program not required. 
Unknown ‘Healthy/unhealthy’ diet score - Mean diet score for SMI group was in the ‘unhealthy’ category, 
with only 22% of SMI group scoring in the ‘healthy’ category.  
Key reasons included fast eating and poor consumption of 
fruits, vegetables & fish. 
Stokes et al. 2004 
(UK) 
 
Cross-sectional SCZ 
100% prescribed APM 
(55% clozapine, 45% FGA) 
Outpatients/residential 
n=20 
General population 
data 
7-day WFR (meals) & diet history/nursing 
observation (snacks). 
Assessed by nutritionist. 
Analysed by NETWISP program 
Recognised 
acceptable measure. 
Energy (kcal) 
Fat (g) 
Sugar (g) 
 SCZ group consumed more energy, sugar & fat compared to 
general population. 
Strassnig et al. 2003 
(USA) 
Cross-sectional SCZ, SAD, PNOS 
Medications not described 
Outpatients 
n=146 
General population 
data 
24-hour recall (using food models) 
Assessor not described. 
Analysed by ESHA Food Processor 
Nutrition Software 7.5 
Recognised 
acceptable measure. 
Energy (kcal) 
Macronutrients (g, %EI) 
Fibre (g) 
Caffeine (mg) 
 
 SMI group consumed more energy, CHO, fat & caffeine 
compared to general population data.  
Higher caffeine intake in smokers. 
Strassnig et al. 2005 
(USA) 
 
Cross-sectional SCZ, SAD, PNOS 
Medications not described 
Outpatients 
n=146 
General population 
data 
24-hour recall (using food models). 
Assessed by trained researcher. 
Analysed by ESHA Food Processor 
Nutrition Software 7.5 
 
Recognised 
acceptable measure. 
Total fat & fat subgroups (g) 
Vitamins A, C & E (mg) 
 SMI group consumed more fat, saturated fat & 
polyunsaturated fat compared to general population data. 
Strassnig et al. 2006 
(USA) 
Cross-sectional SCZ, SAD, PNOS 
Medications not described 
Outpatients 
n=146 
General population 
data 
24-hour recall (with food models). 
Assessor not described. 
Analysed by ESHA Food Processor 
Nutrition Software 7.5 
 
Recognised 
acceptable measure. 
Caffeine (mg)  SMI group consumed more caffeine than general population 
data.  
Caffeine intake positively associated with smoking, but not 
associated with BMI or dietary factors. 
 
Sugawara et al. 2014 
(Japan) 
Cross-sectional SCZ, SAD 
Medications not described 
Outpatients 
n=338 
None Brief self-administered diet history 
questionnaire (BDHQ). 
Assessor not described. 
Analysed by a computer algorithm using 
the Standard Tables of Food 
Composition in Japan. 
Validated against 16-
day diet records in 
Japanese adults. 
Energy (kcal)  
Macronutrients (g/1000kcal) 
EFAs (g/1000kcal) 
Fibre (g/1000kcal) 
Micronutrients (mg, ug/1000kcal) 
 Those following a 'healthy dietary pattern' were less likely to 
be obese.  
Healthy pattern was positively associated with intake of 
protein, fat, dietary fibre, n-3 polyunsaturated fatty acids 
(PUFA), n-6 PUFA, folate, riboflavin, pyridoxine, cobalamin, 
and ascorbic acid & was inversely associated with the intake 
of carbohydrates. 
Sugawara et al. 2016 
(Japan) 
Cross-sectional SCZ 
Medications not described 
Mixed settings 
n=22,072 
 
None Brief survey questionnaire. 
Assessor not described. 
Analysis program not required. 
Unknown Soft drink, cakes or other sweets 
(frequency of intake) 
 27.9% of inpatients & 27.8% consumed soft drink everyday.  
34.6% of inpatients & 28.5% of outpatients consumed soft 
drink >1x week.  
39.3% of inpatients & 36.3% of outpatients consumed cakes 
or other sweets more than once per day. 
Suvusaari et al. 2007 
(Finland) 
 
Cross-sectional SMI 
100% prescribed APM 
Setting not described  
n=118 
 
General population 
data (Health 2000 
study) 
 
Standardised diet-related questions on 
intake of specific foods from Finnish 
Health Examination Survey 
Assessor not described. 
Analysis program not required. 
 
Unknown Healthfulness of diet (based on 
vegetable & saturated fat intake) 
 
 No difference for healthfulness of diet between SMI group and 
general population. 
No difference of healthfulness of diet between diagnoses 
within SMI group. 
Treur et al 1999 
(Multinational) 
  
Cohort SCZ 
100% prescribed SGA 
Outpatients 
n=527 
 
BPD 
100% prescribed SGA 
Outpatients 
n=93 
* 17% of total sample 
prescribed MS 
None Series of questions on the frequency of 
consumption of specific food groups 
Assessed by physician. 
Analysis program not required. 
Unknown Specific food categories 
(frequency of intake) 
 25.5% reported increased in sweet foods & sweetened 
beverage consumption,  
23.6% reported decrease in sweet food/drink consumption.  
Higher weight gain in those who reported increased 
consumption of sweet food/drinks. 
 
Tsuruga et al. 2015 
(Japan) 
Cross-sectional SCZ, SAD 
100% prescribed APM 
(38% APM polypharmacy) 
Outpatients 
n=237 
Control 
n=404 
Brief self-administered diet history 
questionnaire (BDHQ). 
Assessor not described. 
Analysed by a computer algorithm using 
the Standard Tables of Food 
Composition in Japan. 
 
Validated against 16-
day diet records in 
Japanese adults. 
‘Vegetable’ & ‘Cereal’ (bread, 
rice, confectionary) dietary 
patterns  
 Cereal dietary pattern was positively associated with SCZ. 
Vegetable dietary pattern was not associated with SCZ. 
Wallace & Tennant 
1998 
(Australia) 
  
Cross-sectional SMI 
95% prescribed APM 
Outpatients 
n=170 
 
 
None 24-hour recall (with food models) 
Assessed by ‘researcher’ 
Analysis program not described. 
Recognised 
acceptable measure. 
Food groups (servings per day) - All respondents ate less than the five food group 
recommendations. Only 5% of respondents consumed 
recommended amounts of fruit and vegetables. 
Williamson et al. 2015 
(UK) 
Prospective 
Cohort 
FEP 
Medication not described 
Outpatients 
n=143 
 
General population 
data n=1186 
4-day food diary. 
Assessor not described. 
Analysed by NetWISP dietary analysis 
software. 
Recognised 
acceptable measure. 
Energy (kJ) 
Macronutrients (g) 
Non-milk extrinsic sugar (g)  
Micronutrients (mg, ug) 
 FEP group consumed more fat, saturated fat & non-milk 
extrinsic sugar (statistical trend), & less vitamin D, folate & 
selenium compared to general population data.  
No sig. difference in energy intake. 
Winstead 1976 
(Germany/USA) 
Cross-sectional Psychosis 
Inpatients 
n=24 
 
Other mental illness 
Inpatients 
n=11 
 
* 30% of total sample 
prescribed FGA or 
antidepressant. 
 
None Inpatients recorded daily intake of coffee 
Reviewed by inpatient staff & 
subsequently interview for accuracy 
Analysis program not utilised 
 
Unknown Coffee (‘high’ users defined as 
≥5 cups of coffee per day) 
- People with psychosis had a higher incidence of ‘high’ coffee 
users compared to other mental illnesses. 
* SCZ = Schizophrenia, SAD = Schizoaffective disorder, SCZF = Schizophreniform disorder, BAD = Bipolar affective disorder, PNOS = Psychosis not otherwise specified, SMI = Severe mental illness, FEP = First-episode 
psychosis, APM = Antipsychotic medication, SGA = Second Generation Antipsychotic, FGA = First Generation Antipsychotic, LAI = Long Acting Injectable antipsychotic, MS = Mood Stabiliser, FFQ = Food Frequency 
Questionnaire, FA = fatty acids, EFA = essential fatty acids, Fe = iron, Se = selenium, Zn = zinc, CHO = carbohydrate, TFAs = trans fatty acids.  
^ Study design quality scores were based on 10 criterion according the American Academy of Nutrition and Dietetics Quality Criteria Checklist: Primary Research [1] 
Supplementary File 5. 
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1. Was the research question clearly 
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2. Was the selection of study 
subjects/patients free from bias? Y N Y Y Y Y Y U Y Y Y 
3. Were study groups comparable? Y Y Y Y Y N Y U y Y N 
4. Was method of handling withdrawals 
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5. Was blinding used to prevent 
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6. Were intervention/therapeutic 
regimens/exposure factor or procedure 
and any comparison(s) described in 
detail? Were intervening factors 
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7. Were outcomes clearly defined and 
the measurements valid and reliable? N Y Y N N Y N Y Y U Y 
8. Was the statistical analysis 
appropriate for the study design and 
type of outcome indicators? Y Y Y Y Y Y Y Y Y Y Y 
9. Are conclusions supported by results 
with biases and limitations taken into 
consideration? Y Y Y Y Y Y Y Y Y Y Y 
10. Is bias due to study’s funding or 
sponsorship unlikely? Y Y Y Y Y Y Y U Y U Y 
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3. Were study groups comparable? Y Y Y N N N N N N N N 
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5. Was blinding used to prevent 
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1. Was the research question 
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2. Was the selection of study 
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3. Were study groups comparable? N N N N Y Y Y Y N U N 
4. Was method of handling 
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5. Was blinding used to prevent 
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regimens/exposure factor or 
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8. Was the statistical analysis 
appropriate for the study design 
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9. Are conclusions supported by 
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10. Is bias due to study’s funding 
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5. Was blinding used to prevent 
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8. Was the statistical analysis 
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1. Was the research question 
clearly stated? Y Y Y Y Y Y Y Y Y Y Y Y 
2. Was the selection of study 
subjects/patients free from bias? Y N Y N N N N Y Y Y Y N 
3. Were study groups 
comparable? Y N N N N N N N Y N Y N 
4. Was method of handling 
withdrawals described? N N Y Y Y Y Y Y U U U N 
5. Was blinding used to prevent 
introduction of bias? U U U U U U U Y U U U U 
6. Were intervention/therapeutic 
regimens/exposure factor or 
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intervening factors described? N Y Y N Y N N Y N Y N N 
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and the measurements valid and 
reliable? N N Y Y Y Y Y N N N Y Y 
8. Was the statistical analysis 
appropriate for the study design 
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Relevance questions Y Y 
Validity questions 
1. Was the research question 
clearly stated? Y Y 
2. Was the selection of study 
subjects/patients free from bias? Y Y 
3. Were study groups 
comparable? Y N 
4. Was method of handling 
withdrawals described? N U 
5. Was blinding used to prevent 
introduction of bias? U N 
6. Were intervention/therapeutic 
regimens/exposure factor or 
procedure and any comparison(s) 
described in detail? Were 
intervening factors described? N N 
7. Were outcomes clearly defined 
and the measurements valid and 
reliable? Y U 
8. Was the statistical analysis 
appropriate for the study design 
and type of outcome indicators? Y U 
9. Are conclusions supported by 
results with biases and limitations 
taken into consideration? Y U 
10. Is bias due to study’s funding 
or sponsorship unlikely? Y Y 
ALL OF Q2, 3, 6, 7 "YES"?                  
(0 = NO, 1 = YES) 0 0 
NUMBER OF "Y" OUT OF 10 7 4 
 
Overall judgement Neutral  Negative 
 
